LYZZ Capital
16
48M
14
4
0.12
- Areas of investment
Summary
The venture was found in Asia in China. The leading representative office of defined VC is situated in the Shanghai.
The overall number of key employees were 3.
The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The real fund results show that this VC is 30 percentage points more often commits exit comparing to other companies. The high activity for fund was in 2018. The average startup value when the investment from LYZZ Capital is 100-500 millions dollars.
The standard case for the fund is to invest in rounds with 2-3 partakers. The meaningful sponsors for the fund in investment in the same round are Vertex Ventures China, Vertex Ventures, Tahoe Venture. In the next rounds fund is usually obtained by HBM Healthcare Investments AG.
For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most popular portfolio startups of the fund, we may highlight Qpex Biopharma, Alpha Biopharma, Neurelis. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular fund investment industries, there are Medical, Biopharma. The fund has no exact preference in some founders of portfolio startups.
Investments analytics
Analytics
- Total investments
- 16
- Lead investments
- 4
- Follow on index
- 0.12
- Investments by industry
- Biotechnology (12)
- Health Care (7)
- Pharmaceutical (5)
- Therapeutics (5)
- Medical (4) Show 5 more
- Investments by region
-
- United States (9)
- China (6)
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 54M
- Group Appearance index
- 0.94
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Neurelis | 22 Feb 2016 | Biotechnology, Health Care, Medical, Pharmaceutical | Early Stage Venture | United States, California | |
| OncoMyx Therapeutics | 09 Dec 2021 | Biotechnology, Health Diagnostics, Medical, Therapeutics | Early Stage Venture | 50M | United States, Arizona, Phoenix |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.